STRA vs UTI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

STRA and UTI are similarly sized, but STRA trades noticeably cheaper on forward earnings (8.97x vs 19.25x): the market is paying up for UTI's profile and pricing STRA more conservatively, or for faster growth. If you believe in growth, UTI fits: analysts expect its revenue to rise 10% next year, against a 1% decline for STRA. If you believe in paying less for profit, STRA fits: it trades at 8.97x forward earnings, against 19.25x for UTI.

STRA vs UTI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricSTRAUTIWhat it tells you
Market cap$1.15B$986.27MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E8.9719.25Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E163.9529.83Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.481.21Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range5% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book0.792.86How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: STRA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how STRA and UTI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. STRA and UTI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined STRA and UTI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Strategic Education (STRA) do?

Strategic Education, Inc. is a Herndon, Virginia based education services company formed in 2018 when Strayer Education merged with Capella Education. It reports three segments. U.S. Higher Education (USHE) runs Strayer University and Capella University, two largely online institutions serving working adults, with a growing tilt toward nursing and healthcare programs and Capella's self-paced FlexPath format. Australia/New Zealand (ANZ) runs Torrens University Australia, Think Education and Media Design School. Education Technology Services (ETS) includes Workforce Edge, which administers employer-paid education benefits, and Sophia Learning, a low-cost subscription platform for transferable general education credits.

Full STRA guide

What does Universal Technical Institute (UTI) do?

Universal Technical Institute, Inc. (NYSE: UTI) runs postsecondary vocational schools across two reportable segments. The legacy UTI segment trains students in automotive, diesel, motorcycle, marine, welding, CNC and related skilled trades, while the Concorde Career Colleges segment (acquired in 2022) offers allied health, dental, nursing, patient-care and diagnostic programs. The company generates revenue primarily from student tuition, much of it funded through federal Title IV financial aid, and it has been growing student starts and average full-time enrollment at both segments.

Full UTI guide

STRA vs UTI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • STRA drivers: Employer-paid enrollment through Workforce Edge; Healthcare and FlexPath mix shift.
  • UTI drivers: Skilled-trades demand tailwind; Concorde and healthcare diversification.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Regulation is the largest risk. For UTI, uTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business.

STRA or UTI: which should you pick?

If the story you believe is STRA's (Employer-paid enrollment through Workforce Edge), STRA is the more direct way to own it; if it is UTI's (Skilled-trades demand tailwind), UTI is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the STRA and UTI guides.

STRA vs UTI: the full fundamentals

STRA. The trailing P/E is not meaningful because the Q3 2026 impairment of the Australian business nearly erased GAAP earnings; on 2027 consensus the stock trades near ~9x after a ~36% one-month fall. With no debt and ~$139 million of cash and securities, enterprise value sits near ~$1.0 billion, about ~4.5x trailing EBITDA of ~$248 million. The two analysts in Yahoo Finance's count hold a mean target near ~$63 with a hold rating, and fourth-quarter consensus is ~$1.77 of EPS on ~$320 million of revenue.

UTI. The fiscal 2027 outlook reset the earnings path again: at ~$18.17 the stock trades near 30 times trailing EPS of ~$0.60, but guided fiscal 2027 EPS of $0 to $0.09 makes a forward P/E close to meaningless, so the market is valuing UTI on revenue (~1.1x trailing sales) and on adjusted EBITDA guided at $100 to $106 million. The market value of roughly ~$1.0 billion is well under half its mid-2026 level. The mean analyst target of about ~$32 from six analysts still sits far above the price, which shows how wide the gap is between the 2029 plan and what the market is willing to pay for it today.

Headline figures (approximate, November 2026): STRA shows market capitalization ~$1.15 billion at ~$52.49 a share, revenue (ttm) ~$1.29 billion (Q3 2026 ~$325 million, roughly flat YoY), net income (ttm) ~$9.6 million, after a ~$134 million Q3 impairment, q3 2026 adjusted eps ~$1.72 vs ~$1.95 expected; UTI shows revenue (fy2026) ~$897M, +~7.4% YoY, revenue (fq4 2026) ~$235.9M, +~6% YoY, net income (fy2026) ~$33.6M (~$0.60 per share), adjusted ebitda (fy2026) ~$102M after ~$34.6M of growth investment.

The bottom line: STRA vs UTI

STRA and UTI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined STRA and UTI exposure against your real portfolio. It is not an investment adviser.

Wondering how STRA or UTI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Strategic Education

Ask Walnut's AI anything about STRA and see how it fits what you own.

FAQ

What is the difference between STRA and UTI?

+

Strategic Education, Inc. Universal Technical Institute, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is STRA or UTI the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, STRA or UTI?

+

On forward P/E (as of November 2026), STRA trades at 8.97x and UTI at 19.25x, so STRA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both STRA and UTI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of STRA vs UTI?

+

STRA: Regulation is the largest risk. Strayer and Capella depend heavily on federal Title IV aid, so changes under the One Big Beautiful Bill Act, new loan limits and repayment plans effective July 1, 2026, and revived accountability and gainful-employment rules could hit enrollment or eligibility. Capella still faces Department of Education borrower defense fact-finding tied to the Ornelas litigation, and recovery of discharged loans could be material. US enrollment has been flat to down (USHE fell ~1.4% in 2025 and ~1% in Q3 2026, with unaffiliated enrollment down eight quarters running), so growth relies on mix and pricing rather than volume, and management expects 2027 revenue to be flat. In Australia, international student restrictions cut ANZ enrollment ~9% in Q3 and forced a ~$134 million goodwill and intangibles impairment; Torrens also lost its appeal over casual academic pay, with a ~$13.9 million reserve, a related employee class action and possible further costs. A February 2026 cybersecurity incident produced consolidated data-breach suits in Virginia. Competition from low-cost nonprofits such as WGU and SNHU is intense, adjusted EPS has missed consensus in each of the first three quarters of 2026, and the Q3 miss plus a Barrington downgrade took the stock down ~36% in a month. Currency swings also move ANZ results. UTI: UTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business. Near-term profitability has already collapsed on expansion spending: fiscal 2026 net income of ~$33.6 million was down from ~$63 million in fiscal 2025, and fiscal 2027 net income is guided to just $0 to $5 million, so the earnings base the market can value is close to zero for a year. The for-profit education sector carries a history of regulatory scrutiny and reputational risk. Rising labor and real-estate costs can pressure margins, and an economic downturn can cut both ways on enrollment. Admissions execution has now disappointed in consecutive quarters, with fourth-quarter starts up only ~3.3%, and a mix shift toward shorter, lower-priced programs could weigh on revenue per student even if starts recover. New campuses need regulatory approval to open on schedule. Debt of ~$325 million against ~$171 million of cash, plus the revolver and a much larger capex plan, adds balance-sheet exposure that a debt-light company would not carry. Analysts have reset their targets after the report (Truist to $26 from $38, B. Riley to $39 from $45), and the stock fell about 17% over the month to November 20, 2026.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell STRA or UTI; figures are approximate and dated (as of November 2026). Verify current data before investing.